Cite

HARVARD Citation

    Masuda, N. et al. (n.d.). 42PRibociclib (RIB) + endocrine therapy (ET) in Japanese women with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC). Annals of oncology. p. . [Online]. 
  
Back to record